Growing evidence points to gallstones and cholecystitis as an underrecognized risk of GLP-1 RA therapy—pharmacists are well positioned to catch it early.
|Articles|December 17, 2021
Pharmacy Clinical Pearl of the Day: Fetal Alcohol Syndrome
Author(s)Saro Arakelians, PharmD
Fetal alcohol syndrome causes brain damage and growth problems.
Advertisement
Clinical Pearl of the Day: Fetal Alcohol Syndrome
Fetal alcohol syndrome is a condition in a child that results from alcohol exposure during the mother's pregnancy.
Insight:
- Fetal alcohol syndrome causes brain damage and growth problems.
- The problem caused by fetal alcohol syndrome vary from child to child, but defects caused by fetal alcohol syndrome are not reversible.
- There is no amount of alcohol that's known to be safe to consume during pregnancy.
- Symptoms include physical defects, such as vision, heart, joint growth, as well as nervous system problems.
- Causes include alcohol in the bloodstream and reaching the placenta and fetus.
- Treatment may include early intervention, addressing any fetus problems, vocational and life skills training for the born child, as well as family support for the mother and the child.
Sources:
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
SubscribeAdvertisement
Related to this article
A suspected plague death in Russia has renewed attention on the rare infection. Here's how to spot pneumonic plague and which antibiotics the CDC recommends.
A meta-analysis of 27 trials found 15% lower cardiovascular (CV) event risk per 10-mm Hg SBP reduction, with eGFR declines but no rise in kidney failure.
As earning years peak, so do spending and responsibility—here’s where midcareer pharmacists should focus their financial decision-making.
In the phase 2 ZUPREME 1 trial, the once-weekly amylin analog was well tolerated, with nausea mostly mild and limited to dose escalation.
Post hoc STEP UP data at EASD 2026 show liver fat fell from 8.8% to 3.1% at 72 weeks in a 55-person MRI subgroup, though no placebo comparison was reported.
Despite the controversy surrounding mRNA's role in the COVID-19 response, the technology's broader promise—to prevent, treat, and even cure a host of diseases—is coming into focus.
Age is the leading factor in influenza vaccine selection, and vaccination remains effective well beyond the ideal September-to-October window.
Advertisement
Advertisement